AN-2690
AN-2690 structure
|
Common Name | AN-2690 | ||
|---|---|---|---|---|
| CAS Number | 174671-46-6 | Molecular Weight | 151.931 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 230.8±50.0 °C at 760 mmHg | |
| Molecular Formula | C7H6BFO2 | Melting Point | 120-122 °C | |
| MSDS | Chinese USA | Flash Point | 93.4±30.1 °C | |
Use of AN-2690Tavaborole (AN-2690) is an antifungal agent with activity against Trichophyton species, in a topical solution formulation for the potential treatment of onychomycosis. |
| Name | tavaborole |
|---|---|
| Synonym | More Synonyms |
| Description | Tavaborole (AN-2690) is an antifungal agent with activity against Trichophyton species, in a topical solution formulation for the potential treatment of onychomycosis. |
|---|---|
| Related Catalog | |
| In Vitro | Tavaborole (AN-2690) shows an 8-fold increase in activity against C. neoformans, and an 8-fold increase in activity against A. fumigatus[1]. Tavaborole (AN-2690) obviously inhibit the cells expressing GlLeuRS-D444A, but has no effect on the cells expressing GlLeuRS and GlLeuRS-D444E[2]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 230.8±50.0 °C at 760 mmHg |
| Melting Point | 120-122 °C |
| Molecular Formula | C7H6BFO2 |
| Molecular Weight | 151.931 |
| Flash Point | 93.4±30.1 °C |
| Exact Mass | 152.044495 |
| PSA | 29.46000 |
| LogP | 0.04340 |
| Vapour Pressure | 0.0±0.5 mmHg at 25°C |
| Index of Refraction | 1.526 |
| Hazard Codes | Xi |
|---|---|
| RIDADR | NONH for all modes of transport |
|
~58%
AN-2690 CAS#:174671-46-6 |
| Literature: Anacor Pharmaceuticals Patent: US2007/265226 A1, 2007 ; Location in patent: Page/Page column 59 ; |
|
~67%
AN-2690 CAS#:174671-46-6 |
| Literature: ELI LILLY AND COMPANY Patent: WO2004/9578 A2, 2004 ; Location in patent: Page 36-37 ; WO 2004/009578 A2 |
|
~%
AN-2690 CAS#:174671-46-6 |
| Literature: ANACOR PHARMACEUTICALS INC. Patent: US2007/286822 A1, 2007 ; Location in patent: Page/Page column 48 ; |
|
~%
AN-2690 CAS#:174671-46-6 |
| Literature: Ding, Charles Z.; Zhang, Yong-Kang; Li, Xianfeng; Liu, Yang; Zhang, Suoming; Zhou, Yasheen; Plattner, Jacob J.; Baker, Stephen J.; Liu, Liang; Duan, Maosheng; Jarvest, Richard L.; Ji, Jingjing; Kazmierski, Wieslaw M.; Tallant, Matthew D.; Wright, Lois L.; Smith, Gary K.; Crosby, Renae M.; Wang, Amy A.; Ni, Zhi-Jie; Zou, Wuxin; Wright, Jon Bioorganic and Medicinal Chemistry Letters, 2010 , vol. 20, # 24 p. 7317 - 7322 |
|
~%
AN-2690 CAS#:174671-46-6 |
| Literature: Baker, Stephen J.; Zhang, Yong-Kang; Akama, Tsutomu; Lau, Agnes; Zhou, Huchen; Hernandez, Vincent; Mao, Weimin; Alley; Sanders, Virginia; Plattner, Jacob J. Journal of Medicinal Chemistry, 2006 , vol. 49, # 15 p. 4447 - 4450 |
|
~%
AN-2690 CAS#:174671-46-6 |
| Literature: Gunasekera, Dinara S.; Gerold, Dennis J.; Aalderks, Nathan S.; Chandra, J. Subash; Maanu, Christiana A.; Kiprof, Paul; Zhdankin, Viktor V.; Reddy, M. Venkat Ram Tetrahedron, 2007 , vol. 63, # 38 p. 9401 - 9405 |
![2-bromo-5-fluoro-[1-(methoxymethoxy)methyl]benzene structure](https://image.chemsrc.com/caspic/288/845301-93-1.png)
| Tavaborole |
| 5-fluoro-1-hydroxy-3H-2,1-benzoxaborole |
| Kerydin |
| AN 2690 |
| onychomycosis |
| UNII-K124A4EUQ3 |
| 2,1-Benzoxaborole, 5-fluoro-1,3-dihydro-1-hydroxy- |
| 5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol |
| 5-fluoro-3H-benzo[c][1,2]oxaborol-1-ol |
| 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole |
| 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole |
| 5-fluorobenzo[c][1,2]oxaborol-1(3H)-ol |
| 5-Fluoro-2,1-benzoxaborol-1(3H)-ol |
| Tavaborole (USAN) |
| 2,1-Benzoxaborole,5-fluoro-1,3-dihydro-1-hydroxy |
| AN-2690 |